Location History:
- College Station, TX (US) (1997 - 2000)
- Fayetteville, AR (US) (2002 - 2024)
Company Filing History:
32 out of 836 
21 out of 1,245 
2 out of 108 
Years Active: 1997-2025
Title: The Innovative Contributions of Billy M. Hargis
Introduction
Billy M. Hargis is a prominent figure in the field of immunology and vaccine development, located in College Station, Texas. With an impressive portfolio of 37 patents, Hargis has made significant strides in enhancing immune responses and improving vaccine formulations against infectious diseases.
Latest Patents
Among his latest inventions, Hargis has focused on compositions and methods for enhancing immune responses and limiting infections. Notably, one patent describes vaccine vectors designed to enhance the immune response to Apicomplexan parasites, significantly reducing morbidity and mortality associated with subsequent infections. These vaccine vectors incorporate a polynucleotide encoding a Rhomboid polypeptide, along with an optional immune-stimulatory polypeptide that is suitably expressed on the surface of the vector.
Another critical patent involves mucosal adjuvants and delivery systems. The adjuvants are composed of chitosan cross-linked with an aldehyde or mannosylated chitosan and include methods for their production and integration with antigens. The resulting adjuvant-antigen combinations are valuable in vaccine formulations intended for vaccinating animals against specific antigens and enhancing immune responses in subjects.
Career Highlights
Hargis has had a fruitful career working with reputable institutions, including the University of Arkansas and the Texas A&M University System. His work in these organizations has contributed greatly to the advancement of vaccine technology and immune response mechanisms. His extensive research has influenced both academic and practical approaches to immunology.
Collaborations
Throughout his career, Billy M. Hargis has collaborated with esteemed colleagues such as Luc Berghman and Lisa Bielke. These partnerships have facilitated innovative research efforts and contributed to a deeper understanding of immune responses and vaccine efficacy.
Conclusion
Billy M. Hargis's contributions to the field of immunology and vaccine development are remarkable. With 37 patents to his name, his ongoing research and innovative approaches are set to greatly impact the future of vaccine technology and public health. His collaboration with leading institutions and experts in the field further solidifies his status as a leading inventor and innovator in the realm of enhancing immune responses against infectious diseases.